



PATENT 08/16/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of

Woodward et al

Serial No: n/a

Filed: Submitted herewith

For: CYCLOPENTANE HEPTANOIC  
ACID, 2-CYCLOALKYL OR  
ARYLALKYL DERIVATIVES AS  
THERAPEUTIC AGENTS

Group Art Unit: 1209

Examiner: M. Cebulak

#3


PRELIMINARY AMENDMENT

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Please cancel claims 2 through 25.

26. (New Claim) A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



wherein R<sup>1</sup> =hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C<sub>1</sub>-C<sub>12</sub> alkyl cycloalkyl or aryl; and R<sup>2</sup> = Cl or CF<sub>3</sub>.

27. (New Claim) The method of claim 26, wherein R<sup>1</sup> is selected from the group consisting of H, CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub> and C(CH<sub>3</sub>)<sub>3</sub>.

28. (New Claim) The method of claim 26, wherein R<sup>1</sup> is selected from the group consisting of Na<sup>+</sup> and CH<sub>3</sub>N<sup>+</sup>(CH<sub>2</sub>OH)<sub>3</sub>.

SEARCHED  
INDEXED  
MAILED

B  
cont.

29. (New Claim) The method of claim 26, wherein R<sup>2</sup> is Cl.

30. (New Claim) The method of claim 27, wherein R<sup>2</sup> is CF<sub>3</sub>.

31. (New Claim) The method of claim 26, wherein between about 0.001 and about 1000 µg/eye of a compound of formula (I) is administered.


*B*  
*Cont.*

32. (New Claim) The method of claim 31, wherein between about 0.01 and about 100 µg/eye of a compound of formula (I) is administered.

33. (New Claim) The method of claim 31, wherein between about 0.05 and about 10 µg/eye of a compound of formula (I) is administered.

*RECEIVED  
MAY 20 1992  
U.S. PATENT AND TRADEMARK OFFICE*

34. (New Claim) A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension in primates, comprising a therapeutically effective amount of a compound of formula:



wherein: R<sup>1</sup> = hydrogen, a cationic salt moiety, a pharmaceutically acceptable amine moiety or C<sub>1</sub>-C<sub>12</sub> alkyl, cycloalkyl or aryl; and R<sup>2</sup> = Cl or CF<sub>3</sub>.

35. (New Claim) The composition of claim 34, wherein R<sup>1</sup> is selected from the group consisting of H, CH<sub>3</sub>, CH(CH<sub>3</sub>)<sub>2</sub> and C(CH<sub>3</sub>)<sub>3</sub>.

36. (New Claim) The composition of claim 34, wherein R<sup>1</sup> is selected from the group consisting of Na<sup>+</sup> and CH<sub>3</sub>N<sup>+</sup>(CH<sub>2</sub>OH)<sub>3</sub>.

37. (New Claim) The composition of claim 34, wherein R<sup>2</sup> is Cl.


38. (New Claim) The composition of claim 34, wherein R<sup>2</sup> is CF<sub>3</sub>.

39. (New Claim) The composition of claim 34, wherein between about 0.001 and about 100 µg/eye of a compound of formula (I) is administered.

*Substant 3*  
40. (New Claim) The composition of claim 39, wherein between about 0.01 and about µg/eye of a compound of formula (I) is administered.

*Cont.*  
41. (New Claim) The composition of claim 40, wherein between about 0.05 and about 10 µg/eye of a compound of formula (I) is administered.

*Substant 4*  
42. (New Claim) A method of treating glaucoma and ocular hypertension, which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



wherein: R<sup>1</sup> = a pharmaceutically acceptable ester moiety; and R<sup>2</sup> = Cl or CF<sub>3</sub>.

43. (New Claim) The method of claim 42, wherein R<sup>2</sup> is Cl.

44. (New Claim) The method of claim 42, wherein R<sup>2</sup> is CF<sub>3</sub>.

45. (New Claim) The method of claim 42, wherein between about 0.001 and about 1000 µg/eye of a compound of formula (I) is administered.